| Literature DB >> 25512882 |
Surajit Debnath1, Soma Addya2.
Abstract
Correlating antifungal Azole drug resistance and mis-sense mutations of ERG11 has been paradoxical in pathogenic yeast Candida albicans. Amino acid substitutions (single or multiple) are frequent on ERG11, a membrane bound enzyme of Ergosterol biosynthesis pathway. Presence or absence of mutations can not sufficiently predict susceptibility. To analyze role of mis-sense mutations on Azole resistance energetically optimized, structurally validated homology model of wild C.albicans ERG11 using eukaryotic template was generated. A Composite Search Approach is proposed to identify vital residues for interaction at 3D active site. Structural analysis of catalytic groove, dynamics of substrate access channels and proximity of Heme prosthetic group characterized ERG11 active site. Several mis-sense mutations of ERG11 reported in C.albicans clinical isolates were selected through a stringent criterion and modeled. ERG11 mutants subsequently subjected to a four tier comparative biophysical analysis. This study indicates (i) critical interactions occur with residues at anterior part of 3D catalytic groove and substitution of these vital residues alters local geometry causing considerable change in catalytic pocket dimension. (ii) Substitutions of vital residues lead to confirmed resistance in clinical isolates that may be resultant to changed geometry of catalytic pocket. (iii)These substitutions also impart significant energetic changes on C.albicans ERG11 and (iv) include detectable dynamic fluctuations on the mutants. (v)Mis-sense mutations on the vital residues of the active site and at the vicinity of Heme prosthetic group are less frequent compared to rest of the enzyme. This large scale mutational study can aid to characterize the mutants in clinical isolates.Entities:
Keywords: Active site geometry; Candida albicans; Drug resistance; ERG11; Mis-sense mutations; Protein dynamics; Protein energetics; Vital catalytic residues
Year: 2014 PMID: 25512882 PMCID: PMC4237678 DOI: 10.1186/2193-1801-3-660
Source DB: PubMed Journal: Springerplus ISSN: 2193-1801
Amino acid composition of wildtype ERG11
| Amino acids | Number of residues | Percentage |
|---|---|---|
| Ala (A) | 25 | 4.7% |
| Arg (R) | 25 | 4.7% |
| Asn (N) | 19 | 3.6% |
| Asp (D) | 32 | 6.1% |
| Cys (C) | 4 | 0.8% |
| Gln (Q) | 17 | 3.2% |
| Glu (E) | 30 | 5.7% |
| Gly (G) | 32 | 6.1% |
| His (H) | 13 | 2.5% |
| Ile (I) | 32 | 6.1% |
| Leu (L) | 47 | 8.9% |
| Lys (K) | 35 | 6.6% |
| Met (M) | 13 | 2.5% |
| Phe (F) | 33 | 6.2% |
| Pro (P) | 29 | 5.5% |
| Ser (S) | 37 | 7.0% |
| Thr (T) | 32 | 6.1% |
| Trp (W) | 8 | 1.5% |
| Tyr (Y) | 29 | 5.5% |
| Val (V) | 36 | 6.8% |
Energetic assessment of the initial and final ERG11 model
| Proteins | Energy parameters | ||||||
|---|---|---|---|---|---|---|---|
| Bonds energy (KJ/mole) | Angels energy (KJ/mole) | Torsion energy (KJ/mole) | Improper energy (KJ/mole) | Nonbonded energy (KJ/mole) | Electrostatic energy (KJ/mole) | Toal energy (KJ/mole) | |
| Intitial Model Wild ERG11 | 633.755 | 3071.161 | 2037.510 | 523.60 | -12946.40 | -13659.73 | -20340.652 |
| Final Model Wild ERG11 | 439.711 | 3200.458 | 2128.688 | 657.486 | -16825.04 | -14511.09 | -24909.789 |
|
| 1105.138 | 2512.448 | 2736.639 | 467.556 | -14620.22 | -13716.33 | -21514.770 |
Figure 1Mean Square Displacement 〈 〉 of each residue in the Wild type ERG 11 of
Figure 2Active site residues of the Wild type ERG 11 and template 4K0F.pdb showing the number of possible interactions (Q-SiteFinder). A Active site residues of the Wild type ERG 11 (Amino acid with highest number of interactions (TYR118) and those with a minimum 50% of the highest interactions are star marked). B Active site residues of the template 4K0F showing the number of possible interactions (Amino acid with highest number of interactions (TYR126) and those with a minimum 50% of the highest interactions are star marked).
Figure 3Alignment of Target (ERG11 of ) and the template 4K0F showing composite residues that are predicted to be vital for interactions. SwissModel Sequence Identity 66.21% , Needle Score 1815.5.
Figure 4Composite residues that are predicted to be vital for various interactions in the active site of ERG11.
Figure 5Superimposed model of ERG11 of over the template 4K0F showing the surface of the 14 composite residues. The two substrate access channels and the Inhibitor (bound to the template) are seen. Template shown in Helix-sheet-loop and the model of ERG11 of C.albicans is shown in stick formation.
Figure 6Amino acid residues within 4 Å from the Heme prosthetic group of wild type ERG11 of .
Sequence based prediction of the effect of single amino acid substitutions on ERG11 of
| Sl.no | Mutant | Classifiers | ||||||
|---|---|---|---|---|---|---|---|---|
| Polyphen | Provean | I-MUTANT | MutPred | |||||
| Score | Prediction | Score | Prediction | Effect | DDG value (Kcal/mol) | Probability of deleterious mutation | ||
| 1 | ERG11_D116E | 0.003 (sensitivity: 0.98; specificity: 0.44) | Benign | 0.695 | Neutral | Neutral | -0.47 | 0.672 |
| ERG11_Y118A | 1.000 (sensitivity: 0.00; specificity: 1.00) | Probably Damaging | -9.487 | Deleterious | Large Decrease in stability | -1.83 | 0.764 | |
| 2 | ERG11_P230L | 0.997 (sensitivity: 0.41; specificity: 0.98) | Probably Damaging | -8.773 | Deleterious | Large Decrease in stability | -0.97 | 0.849 |
| 3 | ERG_F380L | 0.831 (sensitivity: 0.95; specificity: 0.82) | Probably Damaging | -3.075 | Deleterious | Large Decrease in stability | -1.28 | 0.583 |
| 4 | ERG11_K342R | 0.005 (sensitivity: 0.97; specificity: 0.74) | Benign | -0.443 | Neutral | Neutral | -0.17 | 0.389 |
Figure 7Phylogeny of ERG11. Fungal and protozoal Cytochromes or ERG11 are in clad A, the higher animals and the sequences of 3D models (from PDB) are clustered as a clad B and C respectively. Clad D is highly diverse sequences.
Selected mutations on ERG11 and their features
| Sl.no | Mutant | Substitution type | References | Comment | Functional nature substituted residues | |
|---|---|---|---|---|---|---|
| Active site residues | Vital residues | |||||
| 1 | ERG11_A114S _Y257H | Double mutant | Xu et al. | Detected in clinical isolates. Described in Azole resistant as well as susceptible isolates. Also described as single mutations (A114S/Y257H) and with various combinations. | None | None |
| 2 | ERG11_D116E | Single mutant | Chau et al. | Detected in clinical isolates. Described in Azole-susceptible and Azole-resistant isolates. Also in combination with other mutations. | D116 | None |
| 3 | ERG11_D116E_K128T_Y132H_G465S | Quadruplet mutant | Ying et al. | Detected in clinical isolates. Detected in Azole resistant strains. Several mutations detected as single mutants. | D116 | Y132 |
| 4 | ERG11_Y118A | Single mutant | Chen et al. | The mutation have been clearly associated with resistance by experimental methods but have not yet been detected in clinical isolates | _ | Y118 |
| 5 | ERG11_Y132H_G450E | Double mutant | Chau et al. | Detected in clinical isolates. Detected only in Azole resistant strains. | _ | Y132 |
| 6 | ERG11_P230L | Single mutant | Li et al. | Detected in clinical isolates. Detected only in Azole resistant strains with increased resistance. | _ | P230 |
| 7 | ERG_F380L | Single mutant | Sanglard and Bille, | Detected in clinical isolates. Associated with Azole resistance. | _ | F380 |
| 8 | ERG11_K342R | Single mutant | Goldman et al. | Detected in clinical isolates. Described only in Azole-susceptible isolate. | None | None |
Mutants from N terminal end of ERG11.